Business Wire

ADVA-OPTICAL-NETWORKING

14.10.2021 09:02:08 CEST | Business Wire | Press release

Share
i3D.net responds to global online gaming boom with ADVA’s TeraFlex™

ADVA (FSE: ADV) today announced that i3D.net has deployed its FSP 3000 TeraFlex to enhance the experience of the 50 million online gamers that i3D.net serves every day. The technology enables the leading hosting solutions provider for the gaming industry to meet rising data demand and customer expectation by significantly increasing capacity and reducing latency in its global transport network. ADVA’s highly flexible solution enables i3D.net to harness previously unused spectrum, optimizing all optical paths and unlocking new value in its existing fiber infrastructure. The TeraFlex terminal will also benefit i3D.net’s enterprise customers, who will be able to leverage low-latency video conferencing applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005058/en/

“As one of the world’s leading high-performance hosting providers, we’re constantly striving to deliver an unbeatable experience for end users. That means investing in the most advanced technology on the market. With our new infrastructure built on the ADVA FSP 3000 TeraFlex , we’re removing any bottlenecks by massively increasing the capacity of our network. And, thanks to its ultra-flexible coherent interfaces with fractional QAM, it ensures maximum data throughput over every link,” said Edwin Verwoerd, VP, engineering, i3D.net. “Low latency is our business, and that’s precisely what our new solution offers. It enables us to provide a winning edge to both players and businesses.“

i3D.net’s specific configuration of the ADVA FSP 3000 TeraFlex is able to carry up to 400Gbit/s of data per wavelength and 800Gbit/s per sled. This open and ultra-flexible 1RU terminal uses software-defined fractional QAM modulation and adaptive baud rate capabilities. As well as significantly boosting the capacity of i3D.net’s worldwide infrastructure, the ADVA FSP 3000 TeraFlex ensures the lowest cost per bit for every fiber path. What’s more, it offers advanced streaming telemetry. This provides operators with real-time performance data, helping them to ensure the highest levels of availability and quality of service for end users. The new solution also features other components of ADVA’s FSP 3000 open optical transport solution , including FSP 3000 QuadFlex optical terminals.

“Our FSP 3000 TeraFlex will be a vital tool for i3D.net. It will be key to seizing new opportunities during the global gaming boom and providing unprecedented levels of quality for its customers. The innovative terminal offers excellent space- and power-efficiency while maximizing fiber utilization. With its flexible bandwidth modulation, it ensures optimal performance even over long-distance links. That’s why our high-performance TeraFlex is ideal for supporting satisfying, immersive gaming,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “It’s great to see another major operator harnessing our TeraFlex technology to unlock extra value in its infrastructure. Spread across six continents, i3D.net’s network will now deliver even more for its customers.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About i3D.net

i3D.net – a Ubisoft company, is one of the leading providers of high-performance hosting and global infrastructure services. We operate a global low-latency network with thousands of servers spread over 40+ point of presence on 6 continents. i3D.net excels in the gaming market and hosts a variety of AAA games. Our mission is to bring the lowest latency to as many users around the world as possible, with the goals of reaching 1 billion users on our platforms by 2025. For more information visit www.i3d.net .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye